臺灣博碩士論文加值系統

近年來接受腎臟替代療法的末期腎臟病患數在世界先進國家都快速增加，形成各國醫療支出之重擔。而關於末期腎臟病之研究，各國皆有針對不同主題介入作研究；台灣之末期腎臟病高盛行率與發生率及其所帶來的每年健保透析費用的龐大支出，對台灣社會以及醫療有其重要意涵，若能針對全球末期腎臟病的研究趨勢予以分析，應可提供國內相關領域研究者參考，探討對國際社會有意義之台灣經驗。本研究使用文獻計量的方式來搜尋SCIE資料庫中世界各國對於末期腎臟病相關發表文獻研究，進而加以分析其中關於成本議題之重要發展方向，並整理該文獻所使用之研究方法。再從此中利用摘要、主題與關鍵字搜尋與成本相關之研究，逐一確認是否針對末期腎臟病與成本所做之研究。結果為在1991-2006年間，完全符合本研究立意之末期腎臟病成本相關研究共有82篇，逐一分類後得出各類主題於各年度的發表數量。研究結果發現，其中以1.腎臟替代療法間、2.血液透析場所、3.紅血球生成素與4.高血壓心臟衰竭用藥等介入所作的成本經濟評估就共49篇佔總量近60%；而與器官移植相關介入ESRD成本效果的主題較為分散，其他支付制度相關、腹膜透析相關、院內感染相關、糖尿病合併相關與其他零星主題等介入ESRD成本議題研究所佔篇數不高，無法成為ESRD成本相關研究主題之主流探討。趨勢結果呈現，未來國內關於ESRD成本相關研究可對國內適用之不同透析方式作成本效果分析(CEA)，並可更深入評估不同透析方式病患之總醫療費用；若將腎臟移植與各透析方式作經濟評估時，則可考慮使用成本效用分析(CUA)。在相關藥物對ESRD成本影響之研究，紅血球生成素之研究呈現飽和狀態，故可思考ESRD併發症其他治療藥物(如VitaminD對腎骨病變治療預防等)之影響，以及近期較受重視高血壓用藥減緩糖尿病腎病變患者進入末期腎臟病之預防成本效益分析，提供政策參考。在本研究中，瞭解文獻計量學之限制，建議未來使用此方法評估研究績效需更保守，且仍需由其他ESRD臨床研究發掘出具前瞻意義之方向。

Recently the End-Stage renal disease (ESRD)patients who accept the Renal Replacement Therapy have increased quickly in advanced countries, and then such the countries have burdened the huge medical expenditure. There are many different topics intervene the ESRD researches in these countries. However, the high prevalence and incidence of ESRD and high dialysis expenditure of Taiwan, there are important implications to Taiwan and medical treatment, so if we analyze the global trend of the ESRD related research, maybe we could provide the result to the researchers in domestic, discussed the Taiwan’s experience which is meaningful to the international . We searched about the global ESRD related literatures by Bibliometrics method in the SCIE database, and found the cost-related researches by using abstract, topic and keayword, analyzed every layer, and then studied the major developing trend and sorted methods of these literatures about cost evaluation. There are 82 literatures during 1991-2006 which are conformed completely to our study’s purpose, and we sort out all kinds of intervention and quantities in every year in these literatures one by one. We find that 1.comparing in the renal replacement therapies, 2.comparing hemodialysis places, 3.EPO and 4.antihypertensive drugs are take turns the four dominant interventions, and these literatures quantity is approaching 60% of our ESRD economic evaluation database. And the interventions about organ transplantation are scatter, others such like reimbursement related, peritoneal dialysis related, nosocomial infection related, diabetic comorbided with ESRD related and other fragmentary topics intervening ESRD economic evaluations researches are infrequent and could not become the trend. The result of trend shows that we could analyze the cost-effectiveness in the different applicative dialysis ways in domestic about the ESRD cost-related domain in the future, and evaluate the total medical costs of these patients of different dialysis ways. And if the renal-transplantation is joined with to be compared, we could use the cost-utility analysis. The researches about how drugs-related impacting on the ESRD cost, the EPO-related research has been during the period of recession. And then we could think about the effect of other ESRD complication drugs on cost, such likes Vitamin D could prevent the ESRD) ,and analyze the cost effectiveness of antihypertensive-drugs be valued recently which could slow down the diabetes pre-ESRD patients into ESRD affect cost to provide for the policy.
In our study, we understand the limits of Bibliometrics method, and suggest that you have to be prudent when using such the method to evaluate a research performance, and find the meaningful direction by other ESRD clinical researches.

誌謝 i
中文摘要 ii
英文摘要 ii
目錄 v
表目錄 vi
圖目錄 vii
第一章 緒論 1
第一節 研究背景 1
第二節 研究目的 2
第二章 文獻探討 3
第一節 文獻計量學(Bibliometrics)之介紹 3
第二節 末期腎臟病及透析治療現況 4
第三節 醫療服務業之經濟評估方法 6
第三章 研究方法 11
第一節 末期腎臟病的文獻計量 11
第二節 末期腎臟病與成本相關之研究資料 27
末期腎臟病成本相關之樣本分析概況 27
第三節 資料篩選 30
第四章 結果 31
第一節 全球末期腎臟病成本研究文獻數據統計 31
第二節 探討末期腎臟病成本各介入主題的演變 36
第五章 結論與建議 54
第一節 結果與討論 54
第二節 研究限制 56
第三節 研究建議 57
參考文獻 59
附錄 69

Alexander, C.M., Lyle, P.A., Keane, W.F., Carides, G.W., Zhang, Z.X. and Shahinfar, S. (2004), Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. Kidney International, 66), S115-S117.
Arnold, W. and Alexander, S. (1997), Cost, work, reimbursement, and the pediatric nephrologist in the United States medicare End-Stage Renal Disease Program. Pediatric Nephrology, 11 (2), 250-257.
Besarab, A. (1993), Optimizing Epoetin Therapy in End-Stage Renal-Disease - the Case for Subcutaneous Administration. American Journal of Kidney Diseases, 22 (2), 13-22
Besarab, A., Flaharty, K.K., Erslev, A.J., Mccrea, J.B., Vlasses, P.H., Medina, F., Caro, J. and Morris, E. (1992), Clinical-Pharmacology and Economics of Recombinant-Human-Erythropoietin in End-Stage Renal-Disease - the Case for Subcutaneous Administration. Journal of the American Society of Nephrology, 2 (9), 1405-1416.
Bruns, F.J., Seddon, P., Saul, M. and Zeidel, M.L. (1998), The cost of caring for end-stage kidney disease patients: An analysis based on hospital financial transaction records. Journal of the American Society of Nephrology, 9 (5), 884-890.
Burgess, E.D., Carides, G.W., Gerth, W.C., Marentette, M.A. and Chabot, I. (2004), Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Canadian Journal of Cardiology, 20 (6), 613-618.
Carides, G.W., Shahinfar, S., Dasbach, E.J., Keane, W.F., Gerth, W.C., Alexander, C.M., Herman, W.H. and Brenner, B.M. (2006), The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Pharmacoeconomics, 24 (6), 549-558.
Chazan, J.A., London, M.R. and Pono, L. (1992), The Impact of Diagnosis-Related Groups on the Cost of Hospitalization for End-Stage Renal-Disease Patients at Rhode-Island-Hospital from 1987 to 1990. American Journal of Kidney Diseases, 19 (6), 523-525
Cheng, I.K.P., Chan, C.Y., Cheng, S.W., Poon, J.F.M., Ji, Y.L., Lo, W.K. and Chan, D.T.M. (1994), A Randomized Prospective-Study of the Cost-Effectiveness of the Conventional Spike, O-Set, and Uvxd Techniques in Continuous Ambulatory Peritoneal-Dialysis. Peritoneal Dialysis International, 14 (3), 255-260.
Chertow, G.M., Paltiel, A.D., Owen, W.F. and Lazarus, J.M. (1996), Cost-effectiveness of cancer screening in end-stage renal disease. Archives of Internal Medicine, 156 (12), 1345-1350.
Clark, W.F., Churchill, D.N., Forwell, L., Macdonald, G. and Foster, S. (2000), To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. Canadian Medical Association Journal, 162 (2), 195-198.
Czyrny, J.J. and Merrill, A. (1994), Rehabilitation of Amputees with End-Stage Renal-Disease - Functional Outcome and Cost. American Journal of Physical Medicine & Rehabilitation, 73 (5), 353-357.
De Vecchi, A.F., Dratwa, M. and Wiedemann, M.E. (1999), Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: costs and reimbursement/funding of ESRD therapies. Nephrology Dialysis Transplantation, 14), 31-41
de Wit, G.A., Ramsteijn, P.G. and de Charro, F.T. (1998), Economic evaluation of end stage renal disease treatment. Health Policy, 44 (3), 215-232.
Diana B. Petitti (2002), Meta-analysis, decision analysis and cost-effectiveness analysis: Methods for Quantitative Synthesis in Medicine.2nd ed. Oxford: Oxford University Press.
Douzdjian, V., Escobar, F., Kupin, W.L., Venkat, K.K. and Abouljoud, M.S. (1999), Cost-utility analysis of living-donor kidney transplantation followed by pancreas transplantation versus simultaneous pancreas-kidney transplantation. Clinical Transplantation, 13 (1), 51-58.
Douzdjian, V., Ferrara, D. and Silvestri, G. (1998), Cost-utility analysis of pancreas transplantation compared to other treatment options for type I diabetics with end-stage renal disease. Transplantation Proceedings, 30 (2), 278
Douzdjian, V., Ferrara, D. and Silvestri, G. (1998), Treatment strategies for insulin-dependent diabetics with ESRD: A cost-effectiveness decision analysis model. American Journal of Kidney Diseases, 31 (5), 794-802.
DurandZaleski, I., BastujiGarin, S., Zaleski, S., Weil, B. and Rostoker, G. (1996), A cost analysis of the prevention of end-stage renal disease: Immunoglobulin therapy for IgA nephropathy. Medical Decision Making, 16 (4), 326-334.
Gerth, W.C., Remuzzi, G., Viberti, G., Hannedouche, T., Martinez-Castelao, A., Shahinfar, S., Carides, G.W. and Brenner, B. (2002), Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney International, 62, S68-S72.
Goeree, R., Manalich, J., Grootendorst, P., Beecroft, M.L. and Churchill, D.N. (1995), Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clinical and Investigative Medicine-Medecine Clinique et Experimentale, 18 (6), 455-464.
Gonzalez-Perez, J.G., Vale, L., Stearns, S.C. and Wordsworth, S. (2005), Hemodialysis for end-stage renal disease: A cost-effectiveness analysis of treatment options. International Journal of Technology Assessment in Health Care, 21 (1), 32-39.
Gordois, A., Nobes, M., Toohey, M. and Russ, G. (2006), Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia. Clinical Transplantation, 20 (4), 526-536.
Herman, W.H., Shahinfar, S., Carides, G.W., Dasbach, F., Gerth, W.C., Alexander, C.M., Cook, J.R., Keane, W.F. and Brenner, B.M. (2003), Losartan reduces the costs associated with diabetic end-stage renal disease - The RENAAL study economic evaluation. Diabetes Care, 26 (3), 683-687.
Hirth, R.A., Held, P.J., Orzol, S.M. and Dor, A. (1999), Practice patterns, case mix, medicare payment policy, and dialysis facility costs. Health Services Research, 33 (6), 1567-1592.
Hirth, R.A., Tedeschi, P.J. and Wheeler, J.R.C. (2001), Extent and sources of geographic variation in medicare end-stage renal disease expenditures. American Journal of Kidney Diseases, 38 (4), 824-831.
Holohan, T.V. (1996), Cost-effectiveness modeling of simultaneous pancreas-kidney transplantation. International Journal of Technology Assessment in Health Care, 12 (3), 416-424.
Hooi, L.S., Lim, T.O., Goh, A., Wong, H.S., Tan, C.C., Ahmad, G. and Morad, Z. (2005), Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology, 10 (1), 25-32.
Hornberger, J., Best, J., Geppert, J. and McClellan, M. (1998), Risks and costs of end-stage renal disease after heart transplantation. Transplantation, 66 (12), 1763-1770.
Hornberger, J.C., Brown, B.W. and Halpern, J. (1995), Designing A Cost-Effective Clinical-Trial. Statistics in Medicine, 14 (20), 2249-2259.
Hornberger, J.C., Garber, A.M. and Jeffery, J.R.(1997), Mortality, hospital admissions, and medical costs of end-stage renal disease in the United States and Manitoba, Canada. Medical Care, 35 (7), 686-700.
Hsu, C.Y., Vittinghoff, E., Lin,F., & Shlipak, M.G.(2004).The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Annual of Internal Medicine, 141:95-101.
Hunink, M.G. and G.P. P., Decision Making in Health and Medicine: Integrating Evidence and Values. 2001, Cambridge, UK: Cambridge University Press.
Hurlbert, S.N., Mattos, M.A., Henretta, J.P., Ramsey, D.E., Barkmeier, L.D., Hodgson, K.J. and Sumner, D.S. (1998), Long-term patency rates, complications and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis access: a prospective study that compares Impra versus Gore-tex grafts. Cardiovascular Surgery, 6 (6), 652-656.
Hutchinson, F.N. and Jones, W.J. (1997), A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. American Journal of Kidney Diseases, 29 (5), 651-657.
Huybrechts, K.F., Caro, J.J., Wilson, D.A. and O''Brien, J.A. (2005), Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value in Health, 8 (5), 549-561.
Hynes, D.M., Stroupe, K.T., Greer, J.W., Reda, D.J., Frankenfield, D.L., Kaufman, J.S., Henderson, W.G., Owen, W.F., Rocco, M.V., Wish, J.B., Kang, J. and Feussner, J.R. (2002), Potential cost savings of erythropoietin administration in end-stage renal disease. American Journal of Medicine, 112 (3), 169-175.
Ifudu, O. and Friedman, E.A. (1997),Economic implications of inadequate response to erythropoietin in patients with end-stage renal disease. Dialysis & Transplantation, 26 (10), 664-&
Jacobs, C. (1997), The costs of dialysis treatments for patients with end-stage renal disease in France. Nephrology Dialysis Transplantation,12), Suppl 1:29-32.
Joyce, A.T., Iacoviello, J.M., Nag, S., Sajjan, S., Jilinskaia, E., Throop, D., Pedan, A., Ollendorf, D.A. and Alexander, C.M. (2004), End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care, 27 (12), 2829-2835.
Karlberg, I. (1992), Cost-Analysis of Alternative Treatments in End-Stage Renal-Disease. Transplantation Proceedings, 24 (1), 335
Karlberg, I. and Nyberg, G. (1995),Cost-Effectiveness Studies of Renal-Transplantation. International Journal of Technology Assessment in Health Care, 11 (3), 611-622.
Keller Wolfgang,Geographic Localization of International Technology Diffusion.2002, forthcoming in American Economic Review.
Kirby, L. and Vale, L. (2001),Dialysis for end-stage renal disease - Determining a cost-effective approach. International Journal of Technology Assessment in Health Care, 17 (2), 181-189.
Kooistra MP, Vos J, Koomans HA, et al. (1998), Daily home haemodialysis in The Netherlands:effects on metabolic control,haemodynamics,and quality of life.Nephrol Dial Transplant, 13:2853-2860.
Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Muirhead N.(1996), A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50:235 -242.
Lee, H., Manns, B., Taub, K., Ghali, W.A., Dean, S., Johnson, D. and Donaldson, C. (2002), Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. American Journal of Kidney Diseases, 40 (3), 611-622.
Lenisa, L., Castoldi, R., Socci, C., Motta, F., Ferrari, G., Spotti, D., Caldara, R., Secchi, A., Pozza, G. and DiCarlo, V. (1995), Cost-effective treatment for diabetic end-stage renal disease: Dialysis, kidney, or kidney-pancreas transplantation? Transplantation Proceedings, 27 (6), 3108-3113
Lim TO, Lim YN, Wong HS, Ahmad G, Singam TS, Morad Z, Suleiman AB, Rozina G, Ong LM, Hooi LS, Shaariah W, Tan CC, Loo CS. (1999), Cost effectiveness evaluation of the Ministry of Health Malaysia dialysis programme. Med J Malaysia. 54(4):442-52.
Liu, J.W., Su, Y.K., Liu, C.F. and Chen, J.B. (2002), Nosocomial blood-stream infection in patients with end-stage renal disease: excess length of hospital stay, extra cost and attributable mortality. Journal of Hospital Infection, 50 (3), 224-227.
Mackenzie P., Mactier R. (1998), Home haemodialysis in the 1990s. Nephrology Dialysis Transplantation, 13(8), 1944-1948.
Manley, H.J. and Carroll, C.A. (2002), The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Seminars in Dialysis, 15 (1), 45-49.
Manns, B., Meltzer, D., Taub, K. and Donaldson, C. (2003), Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Economics, 12 (11), 949-958.
Manns, B.J., Taub, K., Richardson, R.M.A. and Donaldson, C. (2002), To reuse or not to reuse? An economic evaluation of hemodialyzer reuse versus conventional single-use hemodialysis for chronic hemodialysis patients. International Journal of Technology Assessment in Health Care, 18 (1), 81-93.
Matas, A.J., Gillingham, K.J., Payne, W.D., Dunn, D.L., Gruessner, R.W.G., Sutherland, D.E.R., Schmidt, W. and Najarian, J.S. (1996), A third kidney transplant: Cost-effective treatment for end-stage renal disease? Clinical Transplantation, 10 (6), 516-520.
McFarlane, P.A., Pierratos, A. and Redelmeier, D.A. (2002),Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney International, 62 (6), 2216-2222.
Mohr PE, Neumann PJ, Franco SJ, Marainen J, Lockridge R, Ting G.(2001), The case for daily dialysis: its impact on costs and quality of life. Am J Kidney Dis.37(4):777-89.
Moran, L.J., Carey, P. and Johnson, C.A. (1992),Cost-Effectiveness of Epoetin Alfa Therapy for Anemia of End-Stage Renal-Disease. American Journal of Hospital Pharmacy, 49 (6), 1451-1454.
MP Kooistra, PF Vos.(1999), Daily Home Hemodialysis: Towards a More Physiological Treatment of Patients with ESRD. Seminars In Dialysis, 12 (6), 424–430.
Naidas, O.D., Chan-Licuanan, K.R., Velasco, V.P., Dalay, C.V., Bayog, D.V. and Rosete-Liquete, R.M.O. (1998), Cost effectiveness analysis of alternative treatments of end-stage renal disease: Philippine experience. Transplantation Proceedings, 30 (7), 3116
Naito, H. (2006), The Japanese health-care system and reimbursement for dialysis. Peritoneal Dialysis International, 26 (2), 155-161.
Neylan, J.F., Sullivan, E.M., Steinwald, B. and Goss, T.F. (1998),Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. American Journal of Kidney Diseases, 32 (5), 770-777.
Nissenson, A.R., Dylan, M.L., Griffiths, R.I., Yu, H.T., Dean, B.B., Danese, M.D. and Dubois, R.W. (2005),Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. American Journal of Kidney Diseases, 46 (2), 301-308.
Noyons, E.(2001), ”Bibliometrics Mapping of Science in a Science Policy Contest”, Scientometrics, 50(1), 83-92.
Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. (2002), Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J., 144:440-8.
Peeters P, Rublee D, Just PM.(2000), Joseph A.,Analysis and interpretation of cost data in dialysis: review of Western European literature. Health Policy.Dec; 54(3):209-27.
Petitti D.B. (2000). Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine, 2nd edition. Oxford University Press, Oxford.
Pierratos A.(2000), Daily hemodialysis. Current Opinion in Nephrology & Hypertension,9(6):637-642.
Pizzi, L.T., Patel, N.M., Maio, V.M., Goldfarb, D.S., Michael, B., Fuhr, J.P. and Goldfarb, N.I. (2006),Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. Dialysis & Transplantation, 35 (11), 660-+.
Ploth, D.W., Shepp, P.H., Counts, C. and Hutchison, F. (2003),Prospective analysis of global costs for maintenance of patients with ESRD. American Journal of Kidney Diseases, 42 (1), 12-21.
Powe, N.R., Eggers, P.W. and Johnson, C.B. (1994), Early Adoption of Cyclosporine and Recombinant-Human-Erythropoietin - Clinical, Economic, and Policy Issues with Emergence of High-Cost Drugs. American Journal of Kidney Diseases, 24 (1), 33-41
Powe, N.R., Griffiths, R.I. and Bass, E.B. (1993), Cost Implications to Medicare of Recombinant Erythropoietin Therapy for the Anemia of End-Stage Renal-Disease. Journal of the American Society of Nephrology, 3 (10), 1660-1671.
Powe, N.R., Griffiths, R.I., Anderson, G.F., Delissovoy, G., Watson, A.J., Greer, J.W., Herbert, R.J. and Whelton, P.K. (1993),Medicare Payment Policy and Recombinant Erythropoietin Prescribing for Dialysis Patients. American Journal of Kidney Diseases, 22 (4), 557-567
Reed, S.D., Friedman, J.Y., Engemann, J.J., Griffiths, R.I., Anstrom, K.J., Kaye, K.S., Stryjewski, M.E., Szczech, L.A., Reller, L.B., Corey, G.R., Schulman, K.A. and Fowler, V.G. (2005), Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infection Control and Hospital Epidemiology, 26 (2), 175-183.
Roels, L., Kalo, Z., Boesebeck, D., Whiting, J. and Wight, C. (2003), Cost-benefit approach in evaluating investment into donor action: the German case. Transplant International, 16 (5), 321-326.
Salonen, T., Reina, T., Oksa, H., Sintonen, H. and Pasternack, A. (2003), Cost analysis of renal replacement therapies in Finland. American Journal of Kidney Diseases, 42 (6), 1228-1238.
Sandoz, M.S., Ess, S.M., Keusch, G.W., Schwenkglenks, M. and Szucs, T.D. (2004), Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Medical Weekly, 134 (31-32), 448-458.
Sands, J.J. (2006), Disease management improves end-stage renal disease outcomes. Blood Purification, 24 (4), 394-399.
Schaubel, D.E., Morrison, H.I., Desmeules, M., Parsons, D.A. and Fenton, S.S.A. (1999), End-stage renal disease in Canada: prevalence projections to 2005. Canadian Medical Association Journal, 160 (11), 1557-1563.
Seng, W.K., Hwang, S.J., Han, D.C., Teong, C.C., Chan, J., Burke, T.A., Carides, G.W. and Choi, Y.J. (2005), Losartan reduces the costs of diabetic end-stage renal disease: An Asian perspective. Nephrology, 10 (5), 520-524.
Souchet, T., Zaleski, I.D., Hannedouche, T., Rodier, M., Gaugris, S. and Passa, P. (2003), An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes & Metabolism, 29 (1), 29-35.
Stange, P.V. and Sumner, A.T. (1978), Predicting Treatment Costs and Life Expectancy for End-Stage Renal-Disease. New England Journal of Medicine, 298 (7), 372-378
Stevens, M.E., Summerfield, G.P., Hall, A.A., Beck, C.A., Harding, A.J., Covesmith, J.R. and Paterson, A.D. (1992), Cost-Benefits of Low-Dose Subcutaneous Erythropoietin in Patients with Anemia of End Stage Renal-Disease. British Medical Journal, 304 (6825), 474-477.
Ting GO, Carrie B, Freitas T, Zarghamee S.(1999), Global ESRD costs associated with a short daily hemodialysis program in the USA. Home Hemodial Int. 3:41-4.
Traeger J.,Galland R., Arkouche W., Delawari E.(2001), Short Daily Hemodialysis: A Four-Year Experience., Dialysis & transplantation, 30(2), 76-86.
Wang, T., Abraham, G., Akiba, T., Blake, P., Gokal, R., Kim, M.J., Lee, H.B., Lo, W.K., Lye, W.C., Mathew, M., Sirivongs, D., Tan, S.Y., Tungsanga, K., Yang, W.C. and Lindholm, B. (2002), Peritoneal dialysis in Asia in the 21st century: Perspectives on and obstacles to peritoneal dialysis therapy in Asian countries. Peritoneal Dialysis International, 22 (2), 243-248
Weijnen, T.J.G., van Hamersvelt, H.W., Just, P.M., Struijk, D.G., Tjandra, Y.I., ter Wee, P.M. and de Charro, F.T. (2003), Economic impact of extended time on peritoneal dialysis as a result of using polyglucose: the application of a Markov chain model to forecast changes in the development of the ESRD programme over time. Nephrology Dialysis Transplantation, 18 (2), 390-396.
Weinstein MC, Siegel JE, Garber AM, Lipscombe J, Luce BR, Manning WG & Torrance GW .(1997), ‘Productivity costs, time costs and health-related quality of life: A response to the Erasmus Group’, Health Economics, vol 6, pp 505-510.
Weydevelt, F.C.V., Bacquaert-Dufour, K., Benevent, D., Lavaud, S., Beaud, J.M., Allard, B., Riberi, P. and Dandavino, R. (1999),A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis vs. self-care in-center hemodialysis in France. Dialysis & Transplantation, 28 (2), 70-74.
White, A., Odedina, F., Xiao, H., Campbell, E. and Segal, R. (2006), The economic burden of end-stage renal disease with hyperphosphatemia - A study of Florida Medicaid. Disease Management & Health Outcomes, 14 (2), 99-106.
Winkelmayer, W.C., Weinstein, M.C. and Mittleman, M.A. (2002), Health economic evaluations: The special case of end-stage renal disease treatment. Medical Decision Making, 22 (5), 417-430.
Yang, W.C., Hwang, S.J., Chiang, S.S., Chen, H.F. and Tsai, S.T. (2001), The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan. Diabetes Research and Clinical Practice, (54), S47-S54.
You, J.Q., Hoy, W., Zhao, Y.J., Beaver, C. and Eagar, K. (2002), End-stage renal disease in the Northern Territory: current and future treatment costs. Medical Journal of Australia, 176 (10), 461-465.